Washington, DC—The Alliance to Protect Medical Innovation’s Executive Director Patrick O’Connor released the following statement on the Senate Finance Committee hearing on Drug Pricing in America, Part II:
“Today’s Senate Finance hearing provided an important platform for the world’s leading biopharmaceutical companies to explain the complexity of America’s prescription-drug market. Any meaningful reform needs to include everyone involved in this multilayered supply chain. The CEOs outlined a number of ways to make the system more efficient without sacrificing innovation or patients’ access to the treatments they need.”
The Alliance to Protect Medical Innovation is a nonpartisan group committed to fostering a national conversation on medical innovation and patient access to care that is holistic and fact-based. The Alliance evaluates policy proposals and fact-checks claims affecting biomedical innovation, as well as responds to attacks on this innovation ecosystem. We are committed to preserving the pipeline of breakthrough medicines that reduce costs within the health care system and help people live longer, healthier, and more productive lives. The Alliance receives funding from biopharmaceutical companies and other entities that represent the industry.